$PPCB New Way to Treat Cancer Could Convert Cancer Cells Back into Normal Heathy Cells
https://richardacavalli.wixsite.com/greenplan...-treatment
NANOCAP PROPANC BIOPHARMA IS DEVELOPING ‘PRP’ FOR PROMISING NEW WAY TO TREAT CANCER
Proof of concept study demonstrated 41% of 46 terminal patients treated with Propanc PRP exceeded life expectancy without any serious adverse events
PRP has demonstrated a unique ability to convert cancerous cells back to healthy cells. Post-treatment data shows Colorectal and Pancreatic cancer cells returned to homeostasis (normal cells
National Center for Biotechnology Information published a paper reporting evidence that Trypsinogen and chymotrypsinogen (the ingredients in Propanc PRP) demonstrate anti-tumourigenic potential and sensitizes Cancer Stem Cells which may allow chemotherapy and radiotherapy to be more effective
Propanc has optimized and improved PRP for improved results and is ready to initiate a Phase 1b clinical study in 30 - 40 patients to study the safety and efficacy of PRP with results expected in 2025
Initially targeting Pancreatic and Ovarian cancers with combined TAM of $14.3B and long-term strategy of targeting metastatic solid tumors (~$111B TAM)
Competing cancer therapeutics companies in similar early stages typically support market caps of several hundred million dollars
Propanc Biopharma has raised $23 million to date and market cap is approximately $200,000.
Few will argue that the need for more effective cancer treatment is large and growing every day. Despite significant advancements in chemotherapy, radiation, and immunotherapies, cancer remains one of the leading causes of death and is likely to impact each, and every one of us, or a family member. Cancer deaths continue to rise sharply as CNN recently reported, “Global cancer deaths among men projected to increase by 93% by 2050”.
Advancements in cancer treatment will come from small startups, not big pharma. The drug giants rarely innovate new drugs for anything because they are too risky to develop and their business model is to always avoid risk whenever possible. New drugs are almost always invented and developed by small, or start-up biotech companies, and then big drug companies typically license or buy the drug from the little company after it is derisked by being approved by the FDA or some other foreign regulatory agency. The end goal of little start-ups is to become a big company. If they successfully develop a drug for large markets such as cancer therapeutics and then license it to a large drug company, they will have succeeded with enormous returns for their investors.
Propanc Biopharma is exactly that very small startup that has discovered what appears to be a candidate for a very promising new way to treat cancer.
Their first Proof of Concept study demonstrated that 41% of 46 terminal patients treated with Propanc PRP exceeded life expectancy without any serious adverse events. And their drug PRP was the first unrefined version that nonetheless still yielded remarkable results by significantly extending life expectancy of terminal cancer patients.
The following graph demonstrates a wide spectrum efficacy against several different cancer types.
https://richardacavalli.wixsite.com/greenplan...-treatment
NANOCAP PROPANC BIOPHARMA IS DEVELOPING ‘PRP’ FOR PROMISING NEW WAY TO TREAT CANCER
Proof of concept study demonstrated 41% of 46 terminal patients treated with Propanc PRP exceeded life expectancy without any serious adverse events
PRP has demonstrated a unique ability to convert cancerous cells back to healthy cells. Post-treatment data shows Colorectal and Pancreatic cancer cells returned to homeostasis (normal cells
National Center for Biotechnology Information published a paper reporting evidence that Trypsinogen and chymotrypsinogen (the ingredients in Propanc PRP) demonstrate anti-tumourigenic potential and sensitizes Cancer Stem Cells which may allow chemotherapy and radiotherapy to be more effective
Propanc has optimized and improved PRP for improved results and is ready to initiate a Phase 1b clinical study in 30 - 40 patients to study the safety and efficacy of PRP with results expected in 2025
Initially targeting Pancreatic and Ovarian cancers with combined TAM of $14.3B and long-term strategy of targeting metastatic solid tumors (~$111B TAM)
Competing cancer therapeutics companies in similar early stages typically support market caps of several hundred million dollars
Propanc Biopharma has raised $23 million to date and market cap is approximately $200,000.
Few will argue that the need for more effective cancer treatment is large and growing every day. Despite significant advancements in chemotherapy, radiation, and immunotherapies, cancer remains one of the leading causes of death and is likely to impact each, and every one of us, or a family member. Cancer deaths continue to rise sharply as CNN recently reported, “Global cancer deaths among men projected to increase by 93% by 2050”.
Advancements in cancer treatment will come from small startups, not big pharma. The drug giants rarely innovate new drugs for anything because they are too risky to develop and their business model is to always avoid risk whenever possible. New drugs are almost always invented and developed by small, or start-up biotech companies, and then big drug companies typically license or buy the drug from the little company after it is derisked by being approved by the FDA or some other foreign regulatory agency. The end goal of little start-ups is to become a big company. If they successfully develop a drug for large markets such as cancer therapeutics and then license it to a large drug company, they will have succeeded with enormous returns for their investors.
Propanc Biopharma is exactly that very small startup that has discovered what appears to be a candidate for a very promising new way to treat cancer.
Their first Proof of Concept study demonstrated that 41% of 46 terminal patients treated with Propanc PRP exceeded life expectancy without any serious adverse events. And their drug PRP was the first unrefined version that nonetheless still yielded remarkable results by significantly extending life expectancy of terminal cancer patients.
The following graph demonstrates a wide spectrum efficacy against several different cancer types.
